RGEN
Repligen Corporation · NASDAQ
- Sector Health Technology
- Industry Pharmaceuticals: Major
- Website repligen.com
- Employees(FY) 2025
- ISIN US7599161095
Performance
-6.52%
1W
-5.48%
1M
-9.7%
3M
-19.22%
6M
-22.75%
YTD
-10.76%
1Y
Profile
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. Repligen Corporation was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
Technical Analysis of RGEN 2024-11-20
Technical Scores and Rating
Moving Average Score
Oscillator Score
Technical Rating
Recent News & Updates
- 2024-11-14 08:28
Wolfe Research Initiates Repligen at Peer Perform(MT Newswires)
- 2024-11-13 12:13
- 2024-11-13 09:54
Analyst Report: Repligen Corporation(Morningstar Research)
- 2024-11-13 04:21
- 2024-11-13 02:37
Q3 2024 Repligen Corp Earnings Call(Thomson Reuters StreetEvents)
- 2024-11-13 02:08
- 2024-11-12 19:00
RGEN: Raising target price to $134.00(Argus Research)
- 2024-11-12 13:37
- 2024-11-12 12:09
Top Midday Gainers(MT Newswires)
- 2024-11-12 11:55
Repligen Stock Soars 10% on Record Growth and Bold Moves(GuruFocus.com)
- 2024-11-12 09:10
- 2024-11-12 09:05
- 2024-11-11 19:00
Repligen: Q3 Earnings Snapshot(Yahoo Finance)
- 2024-11-11 18:30
Repligen Reports Third Quarter 2024 Financial Results(Globenewswire)
- 2024-11-11 07:04
- 2024-11-05 19:00
RGEN: Raising target price to $121.00(Argus Research)
- 2024-11-05 07:30
- 2024-11-04 18:30
- 2024-10-31 07:30
Repligen to Report Third Quarter 2024 Financial Results(GlobeNewswire)
- 2024-10-30 19:30
Repligen to Report Third Quarter 2024 Financial Results(Globenewswire)
- 2024-10-23 10:01
- 2024-10-22 10:01
- 2024-10-21 07:05
US Stocks Estimated Below Intrinsic Value In October 2024(Simply Wall St.)
- 2024-10-15 12:45
3 investable themes, categories outside of the AI trade(Yahoo Finance Video)
- 2024-10-08 20:00
RGEN: Lowering target price to $116.00(Argus Research)
- 2024-10-04 23:15
Morningstar | A Weekly Summary of Stock Ideas and Developments in the Companies We Cover(Morningstar Research)
- 2024-10-03 11:55
Analyst Report: Repligen Corporation(Morningstar Research)
- 2024-09-24 11:07
Repligen Opens Training & Innovation Center(MT Newswires)
- 2024-09-24 07:30
- 2024-09-23 19:30
Page 1 of 9
previousnext
Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.